About us
Moving fast to provide better access to botulinum toxin treatments
At AEON Biopharma, we focus exclusively on expanding the therapeutic use of botulinum toxins in patients with debilitating neuromuscular disorders. Our lead product, ABP-450, is being developed as a branded biosimilar to BOTOX®, designed to expand access to high-quality therapeutic neurotoxin treatments and deliver meaningful value across the healthcare system.
Our team
Our team is on a mission to realize the untapped possibilities of therapeutic neurotoxins with our proprietary botulinum toxin complex. Our deep expertise in the development and commercialization of neurotoxins guides us in establishing groundbreaking biosimilarity science that could offer improved access for patients living with painful and often intractable conditions.
Management
Board of Directors
